A SMUG1 Inhibitor Modulates the Excision of Pyrimidine DNA Damage

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• DNA repair enzymes, particularly those surveilling pyrimidine damage, are implicated in resistance to antitumor therapies.
• The DNA base excision repair (BER) enzyme SMUG1 is crucial for removing damaged pyrimidines, including those from cytotoxic drugs like 5-fluorodeoxyuridine (5-FdU).

Purpose of the Study:

• To discover and develop novel inhibitors of the SMUG1 enzyme.
• To create a chemical tool for studying DNA repair pathways and responses to nucleoside-based antitumor drugs.

Main Methods:

• Screening of small molecules for inhibitory activity against the SMUG1 DNA repair enzyme.
• Structure-based optimization of initial hit compounds to enhance specificity and potency.
• Biochemical assays to determine enzyme inhibition (IC50) and assess off-target activities.

Main Results:

• Identified sphingosine kinase inhibitor scaffolds as potential SMUG1 inhibitors.
• Developed compound SU0617, a potent and selective SMUG1 inhibitor with an IC50 of 1.5 ± 0.1 μM.
• Confirmed that SU0617 lacks significant kinase inhibitory activity.

Conclusions:

• SU0617 represents the first described inhibitor scaffold for SMUG1.
• This inhibitor provides a valuable tool for investigating SMUG1's role in DNA repair and drug resistance.
• Further studies can utilize SU0617 to explore base excision repair pathways and cellular responses to therapeutic nucleosides.